Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

OHE

This page shows the latest OHE news and features for those working in and with pharma, biotech and healthcare.

As government rushes through no-deal legislation, UK biotech repeats Brexit plea

As government rushes through no-deal legislation, UK biotech repeats Brexit plea

Research commissioned by the BIA from the Office of Health Economics (OHE) two years ago suggested that the UK would join nations such as Australia, Canada and Switzerland in a ‘tier

Latest news

  • Pharma must engage on the affordability question, says ABPI Pharma must engage on the affordability question, says ABPI

    Professor Adrian Towse, director of the ABPI funded Office of Health Economics, (OHE) said that one of the main reasons was the need for a return on investment on pharma's

  • UK lags behind other countries in use of branded drugs UK lags behind other countries in use of branded drugs

    The research by the Office of Health Economics (OHE) - which receives funding from the drug industry as well as other sources - says that the UK ranked ninth among 13 high-income

  • Orphan drug legislation hailed as success

    diseases. The assessment, commissioned from the Office of Health Economics (OHE) Consulting, reveals that between 2000 and 2004, R&D investment in rare diseases in Europe increased by more than half;

  • North-South divide?

    The October 2009 Office of Health Economics (OHE) report, Access Mechanisms for Orphan Drugs: a Comparative Study of Selected European Countries, states that, of 28 orphan medicines (prevalence < 5 per 10, ... The Scottish system does, therefore, have

  • New compendium reveals UK's health trends

    According to the OHE, in 2006, a generic prescription dispensed in England cost an average of GBP4.76, while a branded prescription cost am average of GBP19.35. ... Cancer. OHE statistics also show that cancer is continuing to become more prevalent, but

More from news
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Managing real world data governance Managing real world data governance

    In a study conducted by OHE Consulting, funded by Lilly, we analysed the current data governance arrangements in eight countries, and proposed an aspirational governance framework based on these analyses. ... is an economist at the Office of Health

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

Parkinson’s disease: past, present and future
Examining the history and complexities of Parkinson’s disease – one of the most prevalent neurodegenerative disorders that affects over 10 million people worldwide...
The 17th World Congress on Controversies in Neurology
This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...

Quick links